Qlucore: Streamlining focus to extend financial runway - Emergers

In Q1’23/24, both sales of Qlucore Omics Explorer and costs were slightly higher than we expected. To extend its runway, Qlucore will concentrate efforts on four cancer indications and implement a cost reduction plan, which will be fully effective by 2024, before CE-marking and sales ramp-up in 2025. With slight adjustments to our forecast, smoothing out the cost curve for the upcoming years, an extended slump in the share, affecting the hypothetical terms of a future capital raise, and Market Cap far below Net cash, we now find support for a fair value at SEK 16-21 (20-26) per share.

Länk till analysen i sin helhet: https://www.emergers.se/qlucore_m/